NeurAxis (NRXS) Stock Price, News & Analysis

Company Overview

NeurAxis, Inc. is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and related disorders. The company’s approach is designed to influence the nervous system through targeted electrical stimulation, with the goal of helping regulate symptoms and improve patient outcomes.

NeurAxis’s principal product is IB-Stim, a small, prescription neuromodulation device that delivers percutaneous electrical nerve field stimulation through electrodes placed around the ear. The therapy is intended to reduce functional abdominal pain associated with disorders such as irritable bowel syndrome and functional dyspepsia, particularly in pediatric and adolescent patients. IB-Stim has received authorization from the U.S. Food and Drug Administration for use in applicable patient populations.

Based in the United States, NeurAxis primarily serves the U.S. healthcare market through physicians, clinics and other healthcare providers. The company’s business is centered on expanding adoption of its neuromodulation technology and evaluating additional applications in conditions involving the brain-gut axis and autonomic nervous system. NeurAxis was established to commercialize medical technologies addressing chronic functional disorders and is led by a management team focused on medical-device development and commercialization.

Key Stats

• Today's Range: $6.14 to $7.74
• 50-Day Range: $5.69 to $7.21
• 52-Week Range: $2.21 to $9.33
• Volume: 1.07 million shs
• Average Volume: 133,871 shs
• Market Capitalization: $87.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

NeurAxis Stock Analysis - MarketRank™

NeurAxis scored higher than 35% of companies evaluated by MarketBeat, and ranked 703rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeurAxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

NeurAxis has a consensus price target of $13.00, representing about 87.3% upside from its current price of $6.94.

Amount of Analyst Coverage

NeurAxis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeurAxis is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeurAxis is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NRXS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeurAxis does not currently pay a dividend.

Dividend Growth

NeurAxis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.64

News Sentiment

NeurAxis has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for NeurAxis this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeurAxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.10% of the stock of NeurAxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.77% of the stock of NeurAxis is held by institutions.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/16/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NRXS
• CIK: 1933567
• Web: neuraxis.com
• Phone: (812) 689-0791
• Fax: N/A
• Employees: 24
• Year Founded: 2011

Price Target and Rating

• Average Price Target for NeurAxis: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +87.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.63 million
• Net Margins: -492.76%
• Pretax Margin: -341.35%
• Return on Equity: N/A
• Return on Assets: -641.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.23

Sales & Book Value

• Annual Sales: $5.32 million
• Price / Sales: 16.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -25.70

Miscellaneous

• Outstanding Shares: 12,558,000
• Free Float: 6,085,000
• Market Cap: $87.15 million
• Optionable: Not Optionable
• Beta: 1.47